23282WAC4
Cytokinetics Inc
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company in South San Francisco that develops muscle-directed medicines for heart and muscle diseases. Its approved drug, MYQORZO (aficamten), treats obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and works too hard. Founded in 1997 by four scientists, including Stanford's James Spudich, the company grew out of research on myosin, the motor protein that powers muscle contraction. The name "Cytokinetics" blends "cyto" (cell) and "kinetics" (motion), reflecting the founders' original study of how cells move.
CONVERTIBLEUnderlying: CYTKCUSIP: 23282WAC4HealthcareUS1 derivative reporter
3.50% Convertible Senior Notes due July 1, 2027
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
